Цитрамон П

Quick links

Choose a section

Quick links to important sections

Advertisements

Цитрамон П

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Цитрамон П

Цитрамон П is a pharmaceutical product formally classified as a Non-opioid Analgesic Combination, utilized for providing generalized symptomatic relief from discomfort and fever. This medicine is a Fixed-Dose Combination (FDC) preparation, meaning it contains multiple active agents within a single, solid oral form, typically a tablet. It is primarily intended to be taken by the oral route to achieve a systemic therapeutic effect throughout the body.


Quick Facts

Property Description
Active Ingredients Acetaminophen, Acetylsalicylic Acid, Caffeine
Form Tablet (Oral Solid Dosage Form)
Pharmacological Class Non-opioid Analgesic Combination
Common Purpose Relief of pain and fever
Origin Synthetic

What Type of Medicine is Цитрамон П?

Цитрамон П is a polycomponent preparation of synthetic origin that falls under the general pharmacological class of combination analgesics and antipyretics. Unlike simple, single-ingredient pain relievers, this product combines agents that address pain and temperature regulation through different mechanisms simultaneously. Its identity as an FDC product distinguishes it from simple agents by aiming for a broader, concurrent range of therapeutic influence. The combination of these specific ingredients is clinically recognized for enhanced overall efficacy in treating acute discomfort. This makes it a common choice for occasional headache relief.


Composition: Acetaminophen, Acetylsalicylic Acid, and Caffeine

The product is defined by its three active ingredients [INN]: Acetaminophen (Paracetamol), Acetylsalicylic Acid (Aspirin), and Caffeine (a xanthine derivative). This tripartite active ingredient profile is central to its efficacy, with the components formulated alongside solid excipients necessary for the tablet dosage form. The inclusion of Caffeine is significant, as it acts as an adjuvant, a substance included to enhance the pain-relieving effects of the primary analgesics and provide mild central nervous system (CNS) stimulation. The specific proportioning of these three synthetic ingredients is a key differentiating factor in this standard combination, often offered as an over-the-counter (OTC) product globally.


General Purpose and Pharmacodynamic Synergy

The general purpose of this medicine is to utilize pharmacodynamic synergy to provide enhanced multi-faceted symptomatic relief. This concept means the combined therapeutic effect of the three ingredients on pain and fever is engineered to be superior to the effect of each agent taken individually. By combining a pain signal blocker (Acetaminophen), an agent with anti-inflammatory properties (Acetylsalicylic Acid), and an effect enhancer (Caffeine), Цитрамон П offers reliable temporary relief from common pain and discomfort. The role of caffeine as a booster for the analgesic components further grounds the formulation in pharmacological evidence.

Advertisements

What side effects are possible with Цитрамон П?

Possible Side Effects and Safety Information

The officially documented safety profile for this fixed-dose combination (Acetaminophen, Acetylsalicylic Acid, and Caffeine) is structured around the inherent risks of its active ingredients, as classified in regulatory documents.

Adverse reactions are grouped by the affected body system, following regulatory System-Organ Classes (SOCs). Common effects often relate to Gastrointestinal Disorders (e.g., nausea, dyspepsia) and Nervous System Disorders (e.g., nervousness, insomnia), with their frequency formally classified by authorities as Common or Uncommon.

Category Documented Adverse Effects (Examples)
Common Nausea, vomiting, dyspepsia, nervousness, dizziness, insomnia.
Serious Gastrointestinal hemorrhage, severe hepatotoxicity, Reye's Syndrome (in pediatrics), severe hypersensitivity reactions.

Serious Adverse Reactions are explicitly highlighted in regulatory labeling. These include the potential for Gastrointestinal Hemorrhage (linked to Acetylsalicylic Acid) and Severe Hepatotoxicity or Liver Damage (a critical risk associated with high cumulative doses of Acetaminophen). Rare but life-threatening events such as anaphylactic shock and Severe Cutaneous Adverse Reactions (SCARs) are also documented.

Safety notes tied to exposure and population are formally stated. Chronic use is associated with an increased risk of gastrointestinal complications and can lead to Medication-Overuse Headache. Specific warnings exist for Older Adults (increased GI risk) and for Pediatrics (due to the risk of Reye's Syndrome with Acetylsalicylic Acid during viral illness), as mandated by government health authorities. Use is generally restricted in individuals with known severe hepatic or renal impairment or active gastrointestinal ulcer disease.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving this fixed-dose combination product (Acetaminophen, Acetylsalicylic Acid, Caffeine) requires immediate and urgent medical intervention, as the toxicity arises from three distinct active ingredients. Government regulatory guidance mandates contacting emergency medical services or a Poison Control Center immediately for any suspected overdose, even if the person appears well, due to the high risk of delayed, severe organ damage.


Documented Overdose Manifestations and Outcomes

Toxicity Type Key Manifestations Listed in Regulatory Documents
Acetaminophen Nausea, vomiting, diaphoresis (sweating), and abdominal pain; progressing to fulminant hepatic necrosis (liver failure) and coagulopathy.
Acetylsalicylic Acid Tinnitus, dizziness, confusion, hyperthermia, metabolic acidosis, and acute respiratory distress.
Caffeine Agitation, restlessness, tremor, and cardiac arrhythmias (tachycardia).

Official Emergency Actions

The most critical outcome is liver damage, which is managed with the specific antidote, N-acetylcysteine (NAC), whose effectiveness is time-dependent. Management also involves symptomatic and supportive treatment, including monitoring for acid-base imbalances. Prolonged hospital observation and serial Liver Function Tests (LFTs) are required due to the risk of delayed toxicity. Individuals with pre-existing hepatic impairment are at increased risk for severe hepatotoxicity.

Advertisements

Therapeutic Uses of Цитрамон П

What Цитрамон П Treats: Main Uses and Benefits

The combination is used to address symptoms related to physical discomfort and systemic imbalance, supporting patients during acute symptomatic episodes. The formulation is relevant for easing symptoms across several domains, including headache management.


Easing Acute Discomfort and Systemic Symptoms

This medication is applied across domains where additional symptomatic support is appropriate, helping manage clusters of symptoms that interfere with daily comfort. Цитрамон П is commonly used to help with conditions characterized by periods of heightened symptoms, such as different types of headaches (including acute migraine attacks), febrile syndrome associated with colds or flu, musculoskeletal aches, menstrual cramps (dysmenorrhea), and acute toothache.

The medication assists in managing distressing symptoms and contributes to easing the overall symptom load during episodes of heightened discomfort.


Quick Fact: Symptomatic Support for Headache and Fever

This formulation is used for managing symptoms related to both physical discomfort and elevated body temperature. It is applied in clinical settings that involve episodic or fluctuating manifestations, helping to address noticeable physiological strain and contributes to improved day-to-day comfort.

Regulatory References

  1. NIH DailyMed
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Цитрамон П?

Regulatory documentation strictly defines the population eligibility for this Acetaminophen, Aspirin, and Caffeine combination, based on patient status and specific pre-existing conditions.


Absolute Contraindications

The medicine is contraindicated for individuals with known hypersensitivity or allergic reactions to Acetaminophen, Aspirin, Caffeine, or any other NSAID. It must not be used by patients with severe hepatic impairment or a history of stomach ulcers or gastrointestinal bleeding.

Its use is prohibited during the third trimester of pregnancy (at or after 30 weeks gestation). Children and teenagers recovering from chickenpox or flu-like symptoms are also contraindicated due to the risk of Reye’s syndrome from the aspirin component.


Age and Conditional Use

Use is generally established for adults (18 years and older). Conditional use is specifically mandated for individuals 60 years or older due to an increased risk of serious stomach bleeding. For patients with pre-existing conditions such as kidney disease, high blood pressure, or heart disease, or for those who frequently consume alcohol, regulatory labels require consultation with a health professional before use. Similarly, use during breastfeeding or the second trimester of pregnancy requires professional guidance.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Цитрамон П (Acetaminophen, Acetylsalicylic Acid, Caffeine) documents several clinically significant interactions, primarily categorized by pharmacokinetic and pharmacodynamic effects.

Contraindicated and High-Risk Combinations

  • Other Acetaminophen-Containing Products: Co-administration is formally restricted to avoid exceeding the daily limit of acetaminophen, which carries a severe risk of hepatotoxicity.
  • Methotrexate: Use with the Acetylsalicylic Acid (ASA) component is contraindicated at higher doses (e.g., ge 15 mg/ week), as ASA reduces renal clearance of Methotrexate, which can increase toxicity.
  • Monoamine Oxidase Inhibitors (MAOIs): Prohibited due to the Caffeine component posing a risk of severe sympathetic response or acute hypertensive episodes.

Exposure and Pharmacodynamic Interactions

  • Anticoagulants (e.g., Warfarin): Restricted co-administration due to the ASA component increasing the risk of hemorrhage. The Acetaminophen component may also potentiate the anticoagulant effect.
  • Enzyme Inducers (e.g., Phenytoin, Carbamazepine): These agents may accelerate Acetaminophen metabolism, which can increase the formation of its toxic intermediate metabolite, raising the risk of liver damage.
  • CYP1A2 Inhibitors (e.g., Fluvoxamine, Ciprofloxacin): These inhibit the metabolic clearance of Caffeine, potentially increasing its plasma concentration and effects.
  • Other NSAIDs: Concomitant use with the ASA component increases the risk of severe gastrointestinal bleeding and ulceration.

Lifestyle and Population Constraints

  • Alcohol (Ethanol): The label explicitly advises restriction, noting that the combination with alcohol heightens the risk of both severe liver damage (from acetaminophen) and gastrointestinal bleeding (from ASA).
  • Children and Teenagers: The ASA component is restricted in those recovering from viral illnesses (e.g., flu-like symptoms, chicken pox) due to the risk of Reye's syndrome.
Advertisements

Mechanism of Action

How Цитрамон П Works: Pharmacodynamic Mechanism

Central and Peripheral Prostaglandin Modulation

The primary pharmacodynamic action, which influences thermoregulation and nociceptive signaling, involves interference with the Arachidonic Acid Cascade. Acetylsalicylic Acid (ASA) creates an irreversible inhibition of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2) both in peripheral tissues and the central nervous system (CNS), resulting in decreased synthesis of prostaglandins (PGE2). Acetaminophen (APAP) provides a distinct, functional inhibition focused predominantly on central COX activity, particularly within the hypothalamus. This combined blockade of the mediators of thermoregulation and nociception results in the modulation of the hypothalamic set point and a decrease in nociceptive signal transmission.

CNS Receptor Antagonism and Pain Pathway Activation

The inclusion of Caffeine and the central action of APAP engage specific pathways in the CNS. Caffeine acts as a competitive antagonist at Adenosine Receptors (A1 and A2A), blocking the inhibitory effects of endogenous adenosine, which leads to enhanced neuronal excitability and cerebral vasoconstriction. Concurrently, an active metabolite of APAP (AM404) modulates TRPV1 and CB1 receptors to activate the brain's descending inhibitory pain pathway. This dual central action influences descending nociceptive pathways and enhances central nervous system (CNS) activity. This complementary interaction establishes a multi-modal mechanistic response.

Advertisements

Dosage and Administration Information

How to Use Цитрамон П: Official Administration Guidelines

The usage of Цитрамон П is defined by a short-term, intermittent dosing protocol strictly based on the oral administration of its solid tablet form. This regimen, which integrates specific dosing, frequency, and duration limits, is established to ensure standardized intake.


Dosing and Frequency

The medicine is administered orally, and the standard adult dose is generally 2 tablets of the common 250 mg / 250 mg / 65 mg strength, taken at the onset of symptoms. Dosing is performed on an as-needed (prn) basis, with subsequent doses scheduled to be taken every 6 hours. To prevent excessive exposure to the active components, a minimum interval of 6 hours between individual administrations is specified.

Maximum Limits and Duration

The absolute maximum intake is restricted to 8 tablets in 24 hours. This maximum daily limit is a core constraint of the official use protocol. The treatment is strictly intended for short-term symptomatic relief. For pain management, the duration should not exceed 10 days, and for fever reduction, use is limited to a maximum of 3 days before further clinical guidance must be sought.

Administration Context and Population Rules

Each dose must be swallowed with a full glass of water to facilitate proper oral administration. The medication is restricted to use by adults and adolescents 12 years of age and older, with certain international labeling specifying a minimum age of 15 years.

Advertisements

Recent Clinical Evidence

Evidence for Use in Acute Migraine Attacks

Research has explored this combination in studies relevant to acute migraine headache attacks, primarily using Randomized Controlled Trials (RCTs) and systematic reviews in adult populations. Studies examined outcomes related to achieving a pain-free state or substantial pain relief within the first few hours, and associated symptoms like nausea and light sensitivity. Findings describe patterns observed in research populations related to these short-term measurements.


Evidence for Use in Episodic Tension-Type Headache

The combination was evaluated in research relevant to episodic tension-type headaches (TTH). These studies monitored the proportion of episodes that reached a desired level of pain response at specific intervals. The evidence contributes to the broader landscape for conditions where symptoms may vary in intensity, showing patterns related to short-term change in discomfort.


Evidence for Use in General Acute Pain and Fever

Research has explored this pharmaceutical class for outcomes related to physical discomfort using established models of acute pain, such as postoperative dental pain. Studies report observations related to the combination effect of the three ingredients over short follow-up periods. Evidence for chronic pain conditions is not present in this research base.


Long-Term Research and Follow-up Durations

The core evidence for the studied indications stems from acute, single-dose clinical trials with short follow-up periods. Consequently, long-term outcomes and effects are not fully established regarding the durability of symptom relief or the progression of underlying conditions.


Research in Specific Study Populations

The core clinical research largely included general adult populations. Data for certain groups, such as older adults or individuals with multiple comorbid conditions, remain insufficient. Results apply only to the populations studied.


Key Evidence Gaps and Areas of Research Uncertainty

A major gap lies in the understanding of outcomes related to the management of chronic or persistent conditions. The structure of the research focuses on temporary symptoms, and long-term outcomes are not well characterized. Evidence quality varies across studies when moving beyond the core headache indications.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Цитрамон П (FAQ)


Q: Is Цитрамон П considered a non-steroidal anti-inflammatory drug (NSAID)?

Official product information indicates that the combination contains Acetylsalicylic Acid (Aspirin), which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). While the product is officially categorized as a combination analgesic, one of its primary ingredients belongs to the NSAID class.


Q: Can I take Цитрамон П if I generally have a sensitive stomach?

Regulatory safety documents list potential side effects such as upset stomach, heartburn, or abdominal discomfort. If the medicine is known to cause stomach upset, official labeling notes that it may be taken with food. The product's official label also notes that individuals with a history of stomach ulcers or GI bleeding are not eligible for use.


Q: Is it true that Цитрамон П is only intended for use with mild pain?

According to official indications, the product is used for the temporary relief of minor aches and pains. Importantly, studies and product labels also specifically state its use for treating acute migraine headache attacks, indicating a broader use.


Q: Why do I sometimes hear conflicting information about the proper use of Цитрамон П?

The medication is intended strictly for short-term, symptomatic relief. Studies indicate that frequent or prolonged use, typically defined as 10 or more days per month, is associated with the development of Medication-Overuse Headache. This distinction between acute and chronic use is a common area of public confusion.


Q: Is Цитрамон П generally considered safe to use before driving or operating machinery?

Regulatory documents list central nervous system effects such as dizziness and nervousness as possible side effects. Because these effects could potentially impair one's ability to drive or safely operate machinery, individuals should be aware of this potential impairment.


Q: Is there scientific evidence that the pain relief from Цитрамон П diminishes over time?

Official product information on the caffeine component suggests that long-term, routine use may lead to physical dependence. This frequent use may also result in a reduced perception of the drug's effectiveness over time (tolerance).


Q: Why do some regulatory documents list specific warnings regarding cardiovascular health?

Regulatory documents note that the caffeine component acts as a stimulant that can temporarily increase heart rate and blood pressure. This mechanism is the basis for specific warnings relating to patients who have pre-existing heart-related or high blood pressure conditions.


Q: Are there different versions or formulations of Цитрамон П available?

Regulatory drug information confirms that the Acetaminophen, Aspirin, and Caffeine combination is supplied in several dosage forms. These commonly include both solid oral tablets and capsules in varying strengths.


Q: How quickly is Цитрамон П expected to provide relief?

Official pharmacological explanations indicate that the inclusion of the caffeine ingredient serves an adjuvant role. This adjuvant effect helps to enhance the speed of absorption for the analgesic components, contributing to a faster expected onset of action.


Q: Are there any known interactions between Цитрамон П and oral contraceptives?

Regulatory reviews of drug interactions suggest a potential interaction with some hormonal oral contraceptives (containing Ethinyl Estradiol). These contraceptives can inhibit the metabolic clearance of the caffeine, potentially increasing the risk of caffeine-related side effects.


Q: Can people with a history of asthma safely consider using Цитрамон П?

Based on official warnings, official warnings apply to individuals with a history of asthma. This is because the Aspirin component is known to have the potential to precipitate an asthmatic reaction in susceptible persons.


Q: What is the general expectation for the duration of pain relief from Цитрамон П?

The expected duration of pain relief is indirectly established by the recommended dosing instructions. Regulatory labels reflect an expected duration of relief that aligns with a typical frequency of approximately every 4 to 6 hours.


Q: Does Цитрамон П interact with common over-the-counter herbal supplements?

Official information indicates that the caffeine ingredient in the product can interact with other caffeine-containing substances. This includes certain over-the-counter herbal supplements, such as guarana or green tea, which could increase the risk of caffeine-related side effects.


Q: Is Цитрамон П officially indicated for use with menstrual cramps?

Yes, regulatory indications confirm that this combination product is officially used for the temporary relief of minor aches and pains. This includes pain associated with premenstrual or menstrual cramps.


Q: Are there any official restrictions on diet or food consumption when taking Цитрамон П?

Official labeling mentions that limiting the consumption of other sources of caffeine (from food and beverages) is generally recommended to manage the risk of caffeine-related side effects. Additionally, consuming grapefruit juice may interfere with the metabolism of the medication.


Q: Is the drug known to cause problems for individuals with certain glucose-related metabolic conditions?

Official product warnings note that individuals with conditions such as Diabetes or G-6-PD deficiency (a glucose-related metabolic condition) are advised to seek professional guidance before use.


Q: Can I use Цитрамон П if I am trying to conceive? (Descriptive eligibility)

According to official regulatory labeling, women of childbearing age who are actively trying to get pregnant are advised to seek professional guidance regarding the benefits and risks of the medication.


Advertisements

How should Цитрамон П be stored and disposed of?

Storage and Disposal of Цитрамон П

The official labeling for Цитрамон П tablets defines specific conditions to maintain the product's stability and ensure safety. The medicine must be stored at Controlled Room Temperature, ideally between 20°C to 25°C (68°F to 77°F). Storage is permitted to briefly exceed this range, up to 30 C.

Required Conditions

Requirement Specific Instruction
Temperature Do not store above the maximum permitted temperature.
Container Keep the container closed tightly after use to protect the tablets from moisture and air.
Child Safety Keep out of the sight and reach of children.

Disposal

It is mandatory not to use the product after the expiration date printed on the packaging. Unused or expired tablets must be disposed of in accordance with local community regulations and should not be discarded carelessly. In case of accidental ingestion, a Poison Control Center must be contacted immediately.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Цитрамон П found in:

A-Z Index: